A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

Sponsor
Guangdong Raynovent Biotech Co., Ltd
Study ID
NCT07139548
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • RAY1225 — DRUG
    Administered SC
  • Semaglutide — DRUG
    Administered SC

Study Details

The reason for this study is to compare the effect of the study drug RAY1225 to semaglutide on blood sugar levels in participants with type 2 diabetes.

Key Dates

Start date
Aug 31, 2025
Status verified
Aug 2025
Primary completion
Dec 1, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
600 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 6mg RAY1225
    6 milligrams (mg) RAY1225 administered subcutaneously (SC) once every two week.
  • Experimental: 9mg RAY1225
    9 mg RAY1225 administered subcutaneously (SC) once every two week.
  • Active Comparator: 1 mg Semaglutide
    1 mg semaglutide administered SC once a week.

Primary Outcome Measure

Change From Baseline in Hemoglobin A1c (HbA1c) (6 mg and 9 mg) [ Time Frame: Baseline,36 Week ]

Central Contacts

Related Studies